Compare Biogen Inc (BIIB) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Biogen Inc trades at $206.44 (market cap $30.13B), while Global X Lithium & Battery Tech ETF trades at $75.26. The key difference: Biogen Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | LIT | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.63 | $91.62 |
52-Week Low | $128.93 | $44.96 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
LIT trades at $75.60, up 1.15% with a bullish technical signal from moving averages and ADX, though RSI indicates overbought conditions. Recent news highlights strong EV sales growth and lithium demand catalysts, but key financial ratios are unavailable. The stock shows tight support at $74 and resistance at $75.
Outlook is positive due to EV and energy storage momentum, but risks include overbought technicals and reliance on lithium market cycles. Investment opportunity hinges on sustained demand growth, while volatility from commodity prices and competition poses challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
